Literature DB >> 8599505

Atypical presentation of 4-aminopyridine overdose.

T A Pickett1, R Enns.   

Abstract

4-Aminopyridine (4-AP) is an investigational drug for the treatment of neurologic disorders including multiple sclerosis (MS). Until recently, relatively little was known about 4-AP toxicity in overdose; the only recorded cases involved neurologic symptoms ranging from mild parasthesias to tonic-clonic seizures. We report a case of accidental 4-AP overdose that resulted in continuous, dystonic, choreoathetoid-type movements that responded to treatment with standard anticonvulsant dosages of benzodiazepines.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8599505     DOI: 10.1016/s0196-0644(96)70277-9

Source DB:  PubMed          Journal:  Ann Emerg Med        ISSN: 0196-0644            Impact factor:   5.721


  6 in total

Review 1.  [4-Aminopyridine (Fampridine). A new attempt for the symptomatic treatment of multiple sclerosis].

Authors:  L Husseini; V I Leussink; B C Kieseier; H-P Hartung
Journal:  Nervenarzt       Date:  2010-02       Impact factor: 1.214

Review 2.  4-aminopyridine toxicity: a case report and review of the literature.

Authors:  Andrew M King; Nathan B Menke; Kenneth D Katz; Anthony F Pizon
Journal:  J Med Toxicol       Date:  2012-09

3.  Impact of extended-release dalfampridine on walking ability in patients with multiple sclerosis.

Authors:  Keith C Hayes
Journal:  Neuropsychiatr Dis Treat       Date:  2011-04-28       Impact factor: 2.570

4.  A Massive Overdose of Dalfampridine.

Authors:  Laura J Fil; Payal Sud; Steven Sattler
Journal:  West J Emerg Med       Date:  2015-12-03

5.  Prolonged Toxic Encephalopathy following Accidental 4-Aminopyridine Overdose.

Authors:  Maria Ballesta Méndez; Vincent van Pesch; Arnaud Capron; Philippe Hantson
Journal:  Case Rep Neurol Med       Date:  2014-04-17

6.  Potent block of potassium channels by MEK inhibitor U0126 in primary cultures and brain slices.

Authors:  Jin-Zhao Wang; Cheng Long; Kai-Yuan Li; Hua-Tai Xu; Li-Lian Yuan; Gang-Yi Wu
Journal:  Sci Rep       Date:  2018-06-11       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.